Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Biodynamics Plc LSE:OBD London Ordinary Share GB00BD5H8572 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
  -0.70 -1.19% 58.30 142,282 16:35:25
Bid Price Offer Price High Price Low Price Open Price
57.00 59.60 58.00 58.00 58.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.46 -4.91 -4.70 54
Last Trade Time Trade Type Trade Size Trade Price Currency
16:29:15 O 2 57.00 GBX

Oxford Biodynamics (OBD) Latest News

More Oxford Biodynamics News
Oxford Biodynamics Investors    Oxford Biodynamics Takeover Rumours

Oxford Biodynamics (OBD) Discussions and Chat

Oxford Biodynamics Forums and Chat

Date Time Title Posts
10/6/202116:15Oxford BioDynamics PLC242
25/3/202116:31OBD-23/03/21-110P-SP might go up exponentially given the potential in the US11

Add a New Thread

Oxford Biodynamics (OBD) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-06-11 15:29:1557.0021.14O
View all Oxford Biodynamics trades in real-time

Oxford Biodynamics (OBD) Top Chat Posts

DateSubject
12/6/2021
09:20
Oxford Biodynamics Daily Update: Oxford Biodynamics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker OBD. The last closing price for Oxford Biodynamics was 59p.
Oxford Biodynamics Plc has a 4 week average price of 55p and a 12 week average price of 55p.
The 1 year high share price is 125p while the 1 year low share price is currently 55p.
There are currently 92,559,771 shares in issue and the average daily traded volume is 68,487 shares. The market capitalisation of Oxford Biodynamics Plc is £53,962,346.49.
10/6/2021
16:15
the ghost who walks: Poor share price performance here since the announcement on the product launch
25/5/2021
17:07
rambutan2: Last time we were around the 60ps, which was the first half of last year, non exec Stephen Diggle via his Vulpes funds, was a regular buyer. Will be interesting to see whether he decides to dip in again. Here is his last appearance: https://investegate.co.uk/oxford-biodynamics--obd-/rns/pdmr-dealing/202005151247180881N/
19/5/2021
17:01
the ghost who walks: No, very strange share price move given the updates
31/3/2021
07:17
multibagger: OBD tying up with a global leader in life sciences can only be good news... Agilent Technologies Inc.is a global leader in life sciences, diagnostics and applied chemical markets. Now in its 20th year delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions and people provide trusted answers to customers' most challenging questions. The company generated revenues of $5.34 billion in fiscal 2020 and employs 16,400 people worldwide. Hxxps://www.investor.agilent.com/overview/default.aspx
31/3/2021
07:14
multibagger: This RNS looks very promising.....good luck all :) RNS excerpts that seems particularly of interest to me from a scientific utility and commercial perspective... "...First commercial microarray kit available for high-resolution 3D genome profiling and biomarker discovery....." "....Harnessing the strengths of Agilent's microarray technology and OBD's 3D genomic recognition algorithms, the EpiSwitch® Explorer Array Kit provides results at a high throughput, with high resolution in a fraction of the time. The Kit simultaneously interrogates almost 1 million 3D genomic sites, providing over ten times more high-value data points than conventional, costly, time-consuming methods of detection, which are limited by high noise to signal ratio. This creates a highly reproducible, unbiased map, which can be used to identify, evaluate, or monitor 3D genomic biomarkers. The newly launched Kit, which is for research use only, will enable a new level of whole genome screening, biomarker discovery, and profiling of the 3D genome. It can assist researchers by analyzing the genome's 3D architecture and the crucial role it plays in gene regulation...." Wed, 31st Mar 2021 07:00 RNS Number : 0865U Oxford BioDynamics PLC Oxford BioDynamics signs supply and resale agreement with Agilent Technologies,and launches EpiSwitch® Explorer Array Kit for R&D use · Agilent Technologies to manufacture custom microarray based on OBD's proprietary probe sets for EpiSwitch® Explorer Array Kit · First commercial microarray kit available for high-resolution 3D genome profiling and biomarker discovery · Kit accompanied by EpiSwitch® Data Portal to enable powerful, intuitive analytics of research data and access to 3D genome knowledgebase · Launch of the EpiSwitch® Explorer Array Kit expands academic and clinical researcher access to OBD's EpiSwitch® technology platform following the launch of its EpiSwitch®CST (COVID-19 Severity Test) Oxford, UK - 31 March 2021- Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for personalized healthcare based on the EpiSwitch® 3D genomics platform, and Agilent Technologies (NYSE: A), a global leader in the life sciences, diagnostics, and applied chemical markets, have signed a supply and resale agreement for the manufacture and sale of the new EpiSwitch® Explorer Array Kit ("Kit"). Under the terms of the agreement, Agilent will supply a custom-made SurePrint G3 CGH Microarray for the Kit, incorporating OBD's proprietary 3D genome probes. OBD has exclusive rights for supply and distribution of the Kit. Harnessing the strengths of Agilent's microarray technology and OBD's 3D genomic recognition algorithms, the EpiSwitch® Explorer Array Kit provides results at a high throughput, with high resolution in a fraction of the time. The Kit simultaneously interrogates almost 1 million 3D genomic sites, providing over ten times more high-value data points than conventional, costly, time-consuming methods of detection, which are limited by high noise to signal ratio. This creates a highly reproducible, unbiased map, which can be used to identify, evaluate, or monitor 3D genomic biomarkers. The newly launched Kit, which is for research use only, will enable a new level of whole genome screening, biomarker discovery, and profiling of the 3D genome. It can assist researchers by analyzing the genome's 3D architecture and the crucial role it plays in gene regulation. Improved understanding of the 3D genome could have a significant impact on patient diagnosis, prognosis of disease response, and determination of treatment options. The global epigenetics market size is expected to reach over $22 billion by 2025, with the kits segment anticipated to experience the greatest growth (>20% CAGR), driven by this need for biomarker development and accurate detection for personalized medicine [2]. The EpiSwitch® platform has already been used to develop the recently launched COVID-19 Severity Test, EpiSwitch® CST. Further tests are being developed in other areas including immuno-oncology response, rheumatoid arthritis and prostate cancer [3-8]. Dr Jon Burrows, CEO of Oxford BioDynamics, said:"EpiSwitch® is already well validated in pharma biomarker discovery and has proven capable of stratifying patients for many biological indications [3-8]. OBD has previously announced the expansion of its strategic focus [1] to bring the platform to the precision medicine market, starting with the launch of our COVID-19 Severity Test and the upcoming launch of an IO test. Alongside this strategy, we are keen that our technology and knowledgebase are made available for research and development by academic and clinical researchers worldwide." He added: "Partnering with industry leader, Agilent, gives important third-party validation to our technology and working together will strengthen the commercial offering of our EpiSwitch® Explorer Array Kit to the global research community." Kevin Meldrum, VP/GM of Agilent Genomics said: "Agilent is the premier provider of custom microarrays and we are excited to secure this partnership with Oxford BioDynamics demonstrating how arrays can enable the development of new technologies, such as EpiSwitch®, beyond gene expression and CGH." To accompany the Explorer Array Kit, OBD will also provide access to their online EpiSwitch® Portal to enable array data analytics and provide biological context for readouts. This Portal comprises of two applications: 1. The EpiSwitch® Analytical Portal (EAP) - to enable statistical analysis of 3D-array data with a wide range of tools 2. The EpiSwitch® Data Portal (EDP) - to provide options to map data to the genome, allowing integration of analysis with other data types (SNPs, Hi-C, ATAC-Seq Chip-Seq, RNA-Seq, etc.) and biological interpretation The EpiSwitch® Explorer Array Kit is now available to purchase from OBD's online store: hxxps://store.oxfordbiodynamics.com. Here, users can also sign up and access the EpiSwitch suite of analytical portals. The Kit is provided with EpiSwitch®-optimized sample preparation reagents for analysis of blood, PBMC and primary cell or cell line samples. -Ends-
31/1/2021
18:46
yellowstoneadvisory: If you are interested in the area of epigenetics and personalised medicine come along to the OBD webinar tomorrow evening at 5.30pm. New CEO Jon Burrows will talk about the progress made over the last year and the exciting prospects for 2021. A covid 19 disease severity test is due to launch this quarter which will identify the risks of a severe outcome, requiring intensive care treatment, from catching Covid. This diagnostic test will use blood samples and is suitable for use before catching the virus. Later in the year the company plans to launch an Immuno Oncology test for cancer patients to determine the response from various treatments. Progress is also being made with the Master Service agreement with a major US Pharma company and on its project with Mitsubishi Tanabe. Register here hxxps://us02web.zoom.us/webinar/register/3416112626695/WN__FHR3NBCTW6WOlIvlTi46g
29/1/2021
07:53
the ghost who walks: Poor share price reaction yesterday, any idea why?
17/12/2020
20:32
rambutan2: Also: Matthew Wakefield, the new Chairman, said: "I have been associated with the company for well over a decade and I am convinced now more than ever of the considerable potential in the EpiSwitch(TM) technology. I am looking forward to leading the Board as Chairman and working with Jon and the team in this next phase of the Company's growth." https://uk.advfn.com/stock-market/london/oxford-biodynamics-OBD/share-news/Oxford-BioDynamics-PLC-Appointment-of-Chairman/83889841
17/12/2020
20:31
rambutan2: Noted: Oxford, UK - 15 December 2020 - Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for personalized healthcare based on the EpiSwitch (TM) 3D genomics platform, announces the expansion of its strategic focus. Since his appointment in March 2020, the Company's new CEO, Dr Jon Burrows, has been assessing Oxford BioDynamics' business, its EpiSwitch(TM) technology, and ways in which the Company can unlock its considerable growth potential and bring its technology pipeline rapidly into the precision medicine market. https://uk.advfn.com/stock-market/london/oxford-biodynamics-OBD/share-news/Oxford-BioDynamics-PLC-Oxford-BioDynamics-to-expan/83900695
16/9/2020
11:53
rambutan2: Unsure how relevant re dates and quite where OBD work fits in to timeline: htTps://www.isrctn.com/ISRCTN31062548
Oxford Biodynamics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
OBD
Oxford Bio..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210612 15:18:15